1.Combination of Obestatin and Bone Marrow Mesenchymal Stem Cells Prevents Aggravation of Endocrine Pancreatic Damage in Type II Diabetic Rats.
Noha I HUSSIEN ; Nesrine EBRAHIM ; Ola M MOHAMMED ; Dina SABRY
International Journal of Stem Cells 2017;10(2):129-143
One of the new promising therapies in treatment of diabetes mellitus is mesenchymal stem cells (MSCs) which have an interesting therapeutic potentiality based on their paracrine effect and transdifferentiation potentiality. Also obestatin improves the generation of functional β cells/islet-like cell clusters in vitro, suggesting implications for cell-based replacement therapy in diabetes. So the aim of this study was to evaluate the effect of combination of both MSCs and obestatin on an experimental model of type II diabetes mellitus (T2DM). Sixty male rats were divided into; group I (control group), group II (T2DM group) induced by administration of high fat diet (HFD) and injection of streptozotocin (STZ) in low dose, group III (T2DM treated with MSCs), group IV (T2DM treated with obestatin), group V (T2DM treated with MSCs and obestatin). Fasting blood glucose, C-peptide, insulin and lipid profile were measured. HOMA-IR and HOMA-β were calculated. Pancreatic expression of insulin, glucagon like peptide -1 (GLP-1) and pancreatic duodenal homeobox 1 (Pdx1) mRNA levels were measured. In addition pancreatic histological changes, insulin and Bax were analyzed by immunohistochemical examination of islets of Langerhans. Diabetic rats showed significant increase in HOMA-IR, serum glucose and lipid profile levels with significant decrease in insulin, HOMA-β, GLP-1 and Pdx1 levels. MSCs and obestatin caused significant improvement in all parameters with more significant improvement in combined therapy. The protective effects afforded by MSCs and obestatin may derive from improvement of the metabolic profile, antiapoptosis and by increase in pancreatic GLP-1and Pdx1 gene expression.
Animals
;
Blood Glucose
;
Bone Marrow*
;
C-Peptide
;
Diabetes Mellitus
;
Diet, High-Fat
;
Fasting
;
Gene Expression
;
Genes, Homeobox
;
Ghrelin*
;
Glucagon
;
Glucagon-Like Peptide 1
;
Humans
;
In Vitro Techniques
;
Insulin
;
Islets of Langerhans
;
Male
;
Mesenchymal Stromal Cells*
;
Metabolome
;
Models, Theoretical
;
Rats*
;
RNA, Messenger
;
Streptozocin
2.Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis.
Nadia EL-MENSHAWY ; Sherin M ABD-AZIZ ; Enas M ELKHAMISY ; Mohammed A EBRAHIM
Blood Research 2018;53(2):138-144
BACKGROUND: Targeted therapy has revolutionized the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapse still occurs because of the presence of quiescent stem cells, termed leukemia propagating cells (LPCs). This study aimed to assess the phenotypic diversity of LPCs in adult patients with Ph+ B-Acute ALL (B-ALL) and to assess its prognostic impact. METHODS: Seventy adults with newly diagnosed Ph+ B-ALL were recruited at the Mansoura Oncology Center. Multiparameter flow cytometry studies of mononuclear blast cells for cluster of differentiation (CD)34, CD38, and CD58 were performed. RESULTS: Seventeen patients had blasts with the pattern of LPCs (CD34+CD38−CD58−), while 53 cases had other diverse phenotypic patterns. The rate of complete response was significantly lower in patients with the LPC phenotype (47% vs. 81%, P=0.006). The median time to achieve a complete response was prolonged in patients with the CD34+CD38−CD58− phenotype (48 vs. 32 days, P=0.016). The three-year overall survival was significantly lower in patients with the CD34+CD38−CD58− phenotype (37% vs. 55% respectively, P=0.028). Multivariate analysis showed that the CD34+CD38− CD58− phenotype was an independent risk factor for overall survival. CONCLUSION: The presence of CD34+CD38−CD58− LPCs at diagnosis allows rapid identification of higher risk patients. Risk stratification of these patients is needed to further guide therapy and develop effective LPCs-targeted therapy to improve treatment outcome.
Adult
;
Diagnosis
;
Flow Cytometry
;
Humans
;
Leukemia*
;
Multipotent Stem Cells
;
Multivariate Analysis
;
Phenotype*
;
Philadelphia Chromosome
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
Prognosis*
;
Recurrence
;
Risk Factors
;
Stem Cells
;
Treatment Outcome
3. Nitric oxide synthase inhibitors protect against brain and liver damage caused by acute malathion intoxication
Omar M.E. ABDEL-SALAM ; Eman R. YOUNESS ; Nadia A. MOHAMMED ; Safinaz Ebrahim EL-TOUKHY ; Noha N. YASSEN ; Yasser A. KHADRAWY ; Amany A. SLEEM
Asian Pacific Journal of Tropical Medicine 2017;10(8):773-786
Objective To investigate the effect of N
4. Novel neuroprotective and hepatoprotective effects of citric acid in acute malathion intoxication
Omar M.E. ABDEL-SALAM ; Eman R. YOUNESS ; Nadia A. MOHAMMED ; Safinaz Ebrahim EL-TOUKHY ; Noha N. YASSEN ; Yasser A. KHADRAWY ; Amany A. SLEEM
Asian Pacific Journal of Tropical Medicine 2016;9(12):1181-1194
Objective To study the effect of citric acid given alone or combined with atropine on brain oxidative stress, neuronal injury, liver damage, and DNA damage of peripheral blood lymphocytes induced in the rat by acute malathion exposure. Methods Rats were received intraperitoneal (i.p.) injection of malathion 150 mg/kg along with citric acid (200 or 400 mg/kg, orally), atropine (1 mg/kg, i.p.) or citric acid 200 mg/kg + atropine 1 mg/kg and euthanized 4 h later. Results Malathion resulted in increased lipid peroxidation (malondialdehyde) and nitric oxide concentrations accompanied with a decrease in brain reduced glutathione, glutathione peroxidase (GPx) activity, total antioxidant capacity (TAC) and glucose concentrations. Paraoxonase-1, acetylcholinesterase (AChE) and butyrylcholinesterase activities decreased in brain as well. Liver aspartate aminotransferase and alanine aminotransferase activities were raised. The comet assay showed increased DNA damage of peripheral blood lymphocytes. Histological damage and increased expression of inducible nitric oxide synthase (iNOS) were observed in brain and liver. Citric acid resulted in decreased brain lipid peroxidation and nitric oxide. Meanwhile, glutathione, GPx activity, TAC capacity and brain glucose level increased. Brain AChE increased but PON1 and butyrylcholinesterase activities decreased by citric acid. Liver enzymes, the percentage of damaged blood lymphocytes, histopathological alterations and iNOS expression in brain and liver was decreased by citric acid. Meanwhile, rats treated with atropine showed decreased brain MDA, nitrite but increased GPx activity, TAC, AChE and glucose. The drug also decreased DNA damage of peripheral blood lymphocytes, histopathological alterations and iNOS expression in brain and liver. Conclusions The study demonstrates a beneficial effect for citric acid upon brain oxidative stress, neuronal injury, liver and DNA damage due to acute malathion exposure.